Elizabeth O'Donnell, Clifton C. Mo, Andrew Yee, Omar Nadeem, Jacob Laubach, J. Rosenblatt, Nikhil C Munshi, S. Midha, D. Cirstea, Pavlina Chrysafi, Nora Horick, Paul Richardson, N. Raje
{"title":"伊沙妥昔单抗、卡非佐米、来那度胺和地塞米松治疗新诊断的、符合移植条件的多发性骨髓瘤患者(SKylaRk):单臂 2 期试验","authors":"Elizabeth O'Donnell, Clifton C. Mo, Andrew Yee, Omar Nadeem, Jacob Laubach, J. Rosenblatt, Nikhil C Munshi, S. Midha, D. Cirstea, Pavlina Chrysafi, Nora Horick, Paul Richardson, N. Raje","doi":"10.1016/s2352-3026(24)00070-x","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":118760,"journal":{"name":"The Lancet Haematology","volume":"42 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial\",\"authors\":\"Elizabeth O'Donnell, Clifton C. Mo, Andrew Yee, Omar Nadeem, Jacob Laubach, J. Rosenblatt, Nikhil C Munshi, S. Midha, D. Cirstea, Pavlina Chrysafi, Nora Horick, Paul Richardson, N. Raje\",\"doi\":\"10.1016/s2352-3026(24)00070-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":118760,\"journal\":{\"name\":\"The Lancet Haematology\",\"volume\":\"42 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Lancet Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2352-3026(24)00070-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2352-3026(24)00070-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial